Petrovax Farm's revenue increased by 43% in 2024

431
1
AK&M 17 November 2026 07:47

Petrovax Pharm's revenue in 2024 increased by 43% to RUB 15.7 billion. compared to a year earlier. This is stated in the company's message.

Since 2019, the company's product portfolio has grown 3 times to 20 products from 6.

Drugs from the retail portfolio and vaccines of the Grippol® family are supplied not only to the Russian market, but also abroad. The export turnover reached 2.3 billion rubles in 2024. Currently, 11 of the company's brands are supplied to 11 EU and EAEU countries.

Petrovax Pharm is a Russian biopharmaceutical solutions company. The portfolio includes original drugs, biosimilars, branded generics and dietary supplements. The company's full-cycle production facilities allow it to produce more than 160 million doses of drugs per year.